Kim Shin Young, Moon Hye Min, Lee Min Kyoung, Chung Youn Jee, Song Jae Yen, Cho Hyun Hee, Kim Mee Ran, Kim Jang Heub
Department of Obstetrics and Gynecology, Seoul St. Mary's Hospital, The Catholic University of Korea College of Medicine, Seoul, Korea.
Obstet Gynecol Sci. 2018 Jan;61(1):127-134. doi: 10.5468/ogs.2018.61.1.127. Epub 2017 Dec 21.
We compared the expression levels of Müllerian inhibiting substance (MIS)/anti-Müllerian hormone type II receptor (AMHRII) in uterine myoma and adenomyosis to evaluate the possibility of using MIS/anti-Müllerian hormone (AMH) as a biological regulator or therapeutic agent in patients with uterine leiomyoma and adenomyosis.
We studied normal uterine myometrium, leiomyoma, endometrial tissue, and adenomyosis from 57 patients who underwent hysterectomy for uterine leiomyoma (22 cases) or adenomyosis (28 cases) and myomectomy for uterine myoma (7 cases). Immunohistochemical staining was used to confirm the MIS/AMHRII protein expression level in each tissue. Reverse transcription-polymerase chain reaction was performed to quantify MIS/AMHRII mRNA expression.
The MIS/AMHRII protein was more strongly expressed in uterine myoma (frequency of MIS/AMHRII expressing cells: 51.95%±13.96%) and adenomyosis (64.65%±4.85%) tissues than that in the normal uterine myometrium (3.15%±1.69%) and endometrium (31.10%±7.19%). In the quantitative analysis of MIS/AMHRII mRNA expression, MIS/AMHRII mRNA expression levels in uterine myoma (mean density: 4.51±0.26) and adenomyosis (6.84±0.20) tissues were higher than that in normal uterine myometrial tissue (0.08±0.09) and endometrial tissue (1.63±0.06).
This study demonstrated that MIS/AMHRII was highly and strongly expressed on uterine myoma and adenomyosis. Our data suggest that MIS/AMH may be evaluated as a biological modulator or therapeutic agent on MIS/AMHRII expressing uterine myoma and adenomyosis.
比较子宫平滑肌瘤和子宫腺肌病中苗勒管抑制物质（MIS）/抗苗勒管激素II型受体（AMHRII）的表达水平，以评估将MIS/抗苗勒管激素（AMH）用作子宫平滑肌瘤和子宫腺肌病患者的生物调节剂或治疗剂的可能性。
我们研究了57例因子宫平滑肌瘤（22例）或子宫腺肌病（28例）接受子宫切除术以及因子宫平滑肌瘤接受肌瘤切除术（7例）患者的正常子宫肌层、平滑肌瘤、子宫内膜组织和子宫腺肌病。采用免疫组织化学染色法确定各组织中MIS/AMHRII蛋白的表达水平。进行逆转录-聚合酶链反应以定量MIS/AMHRII mRNA的表达。
MIS/AMHRII蛋白在子宫平滑肌瘤组织（MIS/AMHRII表达细胞频率：51.95%±13.96%）和子宫腺肌病组织（64.65%±4.85%）中的表达比正常子宫肌层（3.15%±1.69%）和子宫内膜（31.10%±7.19%）中更强。在MIS/AMHRII mRNA表达的定量分析中，子宫平滑肌瘤组织（平均密度：4.51±0.26）和子宫腺肌病组织（6.84±0.20）中MIS/AMHRII mRNA的表达水平高于正常子宫肌层组织（0.08±0.09）和子宫内膜组织（1.63±0.06）。
本研究表明MIS/AMHRII在子宫平滑肌瘤和子宫腺肌病中高表达且表达强烈。我们的数据表明，对于表达MIS/AMHRII的子宫平滑肌瘤和子宫腺肌病，MIS/AMH可作为一种生物调节剂或治疗剂进行评估。
